COVID-19 Vaccine

Development of a COVID-19 vaccine that can be distributed at room temperature has a significant impact on global health and would address an emergent, unmet need.

Engimata has a COVID-19 vaccine and a tetanus vaccine in the pipeline (preclinical stage). Unlike current vaccines they can both be distributed without a need for a cold or ultracold supply chain, improving immunization logistics. Engimata’s vaccine is cost-effective, easy to scale up, and simple to manufacture and distribute outside the cold supply chain. This increases vaccine accessibility and stability, ultimately saving cost, resources, and lives.